Parvathi Mohan
Overview
Explore the profile of Parvathi Mohan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
614
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Holterman A, Nguyen H, Nadler E, Vu G, Mohan P, Vu M, et al.
J Pediatr Surg
. 2021 May;
56(7):1179-1185.
PMID: 33965236
Aims: In RCT of adults with decompensated cirrhosis, GCSF mobilizes hematopoietic stem cells HSC and improves short-term outcome. An FDA-IND for sequential Kasai-GCSF treatment in biliary atresia BA was approved....
2.
Torres C, Badalyan V, Mohan P
JPEN J Parenter Enteral Nutr
. 2021 Apr;
46(1):197-206.
PMID: 33794031
Our aim was to analyze the outcomes in children with short-bowel syndrome (SBS), parenteral nutrition dependence (PND), and intestinal failure-associated liver disease (IFALD) treated in our Intestinal Rehabilitation Program (IRP)...
3.
Leung D, Squires J, Jhaveri R, Kerkar N, Lin C, Mohan P, et al.
J Pediatr Gastroenterol Nutr
. 2020 Aug;
71(3):407-417.
PMID: 32826718
In 1989, a collaboration between the Centers for Disease Control (CDC) and a California biotechnology company identified the hepatitis C virus (HCV, formerly known as non-A, non-B hepatitis virus) as...
4.
Boonsimma P, Crosby K, Mohan P, Puscasiu E, Tanpaiboon P
Eur J Med Genet
. 2020 Aug;
64(1):104034.
PMID: 32781271
Carnitine palmitoyltransferase 1A (CPT1A) deficiency is a rare disorder of hepatic long-chain fatty acid oxidation. Most patients with CPT1A deficiency present with hypoketotic hypoglycemia and hepatic encephalopathy. We describe an...
5.
Deneau M, Mack C, Perito E, Ricciuto A, Valentino P, Amin M, et al.
Hepatology
. 2020 May;
73(3):1074-1087.
PMID: 32464706
Background And Aims: Disease progression in children with primary sclerosing cholangitis (PSC) is variable. Prognostic and risk-stratification tools exist for adult-onset PSC, but not for children. We aimed to create...
6.
Deneau M, Valentino P, Mack C, Alqoaer K, Amin M, Amir A, et al.
J Pediatr Gastroenterol Nutr
. 2019 Oct;
70(1):e12-e17.
PMID: 31651664
Background: Natural history models for primary sclerosing cholangitis (PSC) are derived from adult patient data, but have never been validated in children. It is unclear how accurate such models are...
7.
Deneau M, Perito E, Ricciuto A, Gupta N, Kamath B, Palle S, et al.
J Pediatr
. 2019 Mar;
209:92-96.e1.
PMID: 30878206
Objective: To investigate patient factors predictive of gamma glutamyltransferase (GGT) normalization following ursodeoxycholic acid (UDCA) therapy in children with primary sclerosing cholangitis. Study Design: We retrospectively reviewed patient records at...
8.
Deneau M, Mack C, Abdou R, Amin M, Amir A, Auth M, et al.
Hepatol Commun
. 2018 Nov;
2(11):1369-1378.
PMID: 30411083
Adverse clinical events in primary sclerosing cholangitis (PSC) happen too slowly to capture during clinical trials. Surrogate endpoints are needed, but no such validated endpoints exist for children with PSC....
9.
Deneau M, El-Matary W, Valentino P, Abdou R, Alqoaer K, Amin M, et al.
Hepatology
. 2017 Apr;
66(2):518-527.
PMID: 28390159
Conclusion: PSC has a chronic, progressive course in children, and nearly half of patients develop an adverse liver outcome after 10 years of disease; elevations in bilirubin, gamma-glutamyltransferase, and aspartate...
10.
Iordanskaia T, Koeck E, Rossi C, Mohan P, Schwarz K, Anders R, et al.
J Pediatr Gastroenterol Nutr
. 2014 Aug;
59(6):679-83.
PMID: 25079481
Objectives: Our previous work demonstrated altered messenger RNA expression of integrin β-5 and -8, using an in silico analysis of publically available data from patients with biliary atresia (BA); however,...